- Home
- XLO vs HHS Comparison
XLO vs HHS Comparison
Compare XLO & HHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XLO
- HHS
- Stock Information
- Founded
- XLO 2016
- HHS 1923
- Country
- XLO United States
- HHS United States
- Employees
- XLO N/A
- HHS N/A
- Industry
- XLO Biotechnology: Pharmaceutical Preparations
- HHS Advertising
- Sector
- XLO Health Care
- HHS Consumer Discretionary
- Exchange
- XLO Nasdaq
- HHS Nasdaq
- Market Cap
- XLO 42.2M
- HHS 37.0M
- IPO Year
- XLO 2021
- HHS N/A
- Fundamental
- Price
- XLO $0.72
- HHS $4.51
- Analyst Decision
- XLO Buy
- HHS
- Analyst Count
- XLO 1
- HHS 0
- Target Price
- XLO $4.00
- HHS N/A
- AVG Volume (30 Days)
- XLO 184.0K
- HHS 20.1K
- Earning Date
- XLO 05-08-2025
- HHS 05-16-2025
- Dividend Yield
- XLO N/A
- HHS N/A
- EPS Growth
- XLO N/A
- HHS N/A
- EPS
- XLO N/A
- HHS N/A
- Revenue
- XLO $9,274,000.00
- HHS $185,242,000.00
- Revenue This Year
- XLO $668.96
- HHS $6.54
- Revenue Next Year
- XLO $14.49
- HHS N/A
- P/E Ratio
- XLO N/A
- HHS N/A
- Revenue Growth
- XLO N/A
- HHS N/A
- 52 Week Low
- XLO $0.62
- HHS $4.27
- 52 Week High
- XLO $1.70
- HHS $8.87
- Technical
- Relative Strength Index (RSI)
- XLO 43.73
- HHS 45.63
- Support Level
- XLO $0.71
- HHS $4.77
- Resistance Level
- XLO $0.78
- HHS $4.81
- Average True Range (ATR)
- XLO 0.05
- HHS 0.32
- MACD
- XLO -0.01
- HHS -0.02
- Stochastic Oscillator
- XLO 22.50
- HHS 21.79
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.